Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2019 Earnings Conference Call - Final Transcript
Feb 28, 2020 • 08:00 am ET
Good morning and welcome to Mersana Therapeutics' Fourth Quarter and Year-End 2019 Conference Call. [Operator Instructions] I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.
Good morning. Welcome to Mersana's Fourth Quarter and Year-End 2019 Conference Call. We issued a press release earlier this morning reviewing our fourth quarter 2019 and full year results and business updates, which will be covered on this call. A replay of today's call will be available on the Investors and Media section of our website. After our prepared remarks, we will open the call for Q&A.
Before we begin, I'd like to mention that our call will contain forward-looking statements within the meaning of federal securities laws. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the company's plans to vary materially, including the risks that our early encouraging preclinical results for XMT-1536 are not necessarily predictive as the results of our ongoing or future discovery programs or clinical studies; that the development and identification of the company's product candidates and new platforms will take longer and/or cost more than planned; and that our clinical trials will not be completed on schedule, if at all. These risks are discussed in the company's SEC filings, including, without limitation, the company's annual report on Form 10-K filed on February 28, 2020, and subsequent filings. Except as required by law, the company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
And with that, I'll turn the call over to Anna Protopapas, Mersana's Chief Executive Officer.
Thank you, Sarah. Good morning, everyone, and welcome to our financial and corporate update call for the fourth quarter of 2019. Joining me today with prepared remarks is Brian DeSchuytner, our Senior VP of Finance and Product Strategy. The rest of the management team will be available for your questions. Our accomplishments in 2019 have laid the foundation for a data- and milestone-rich-driven 2020. We made a great deal of headway in advancing 1536 and 1592 and utilizing our innovative ADC platforms to advance our early-stage pipeline with plans for 2 first-in-class development candidates in 2020, including B7-H4 DolaLock ADC and a STING agonist ADC based on our immunosynthen platform for a nascent yet undisclosed target. I will provide an overview of the status of our clinical and early-stage programs and outline our goals and milestones for the remainder of the year, and then Brian will provide our financial results for the fourth quarter and full year 2019. We're going to keep our prepared remarks brief because we just provided a comprehensive corporate update last month in San Francisco.
I'll start with 1536, our first-in-class and wholly owned Dolaflexin ADC targeting that Napi2b. As we at ASCO in 2019, XMT-1536 has shown confirmed